Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDR2 | Q16832 | 7/20 | 0.47 |
| ▸ | KDR | P35968 | 2/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.44 |
| ▸ | MERTK | Q12866 | 5/20 | 0.44 |
| ▸ | JAK3 | P52333 | 3/20 | 0.43 |
| ▸ | JAK1 | P23458 | 2/20 | 0.43 |
| ▸ | TYK2 | P29597 | 1/20 | 0.43 |
| ▸ | TYRO3 | Q06418 | 5/20 | 0.42 |
| ▸ | AXL | P30530 | 3/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.41 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.41 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24392820 | 1.00 | DDR2 (0.47) | DDR2KDRAURKBMERTKJAK3 | |
| SCHEMBL29537623 | 0.88 | DDR2 (0.47) | DDR2KDRAURKBMERTKJAK3 | |
| Pebezertinib SCHEMBL24392854 | 0.88 | JAK3 (0.54) | DDR2KDRAURKBMERTKJAK3 | |
| SCHEMBL24393097 | 0.88 | DDR2 (0.47) | DDR2KDRAURKBMERTKJAK3 | |
| SCHEMBL29537705 | 0.88 | DDR2 (0.46) | DDR2KDRAURKBMERTKJAK3 | |
| SCHEMBL24393090 | 0.88 | DDR2 (0.46) | DDR2KDRAURKBMERTKJAK3 | |
| Pebezertinib SCHEMBL29538037 | 0.86 | JAK3 (0.49) | DDR2KDRAURKBMERTKJAK3 | |
| Trifluoroacetic Acid SCHEMBL29250582 | 0.86 | DDR2 (0.45) | DDR2KDRAURKBMERTKJAK3 | |
| SCHEMBL29250731 | 0.84 | DDR2 (0.44) | DDR2KDRAURKBMERTKJAK3 | |
| SCHEMBL29250575 | 0.84 | MERTK (0.46) | DDR2KDRAURKBMERTKJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240051945-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS, AND MEDICINAL APPLICATIONS THEREOF | BLUEPRINT MEDICINES CORPORATION | 2024-02-15 | — | — | US | disclosed |
| EP-4237418-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS, AND MEDICINAL APPLICATIONS THEREOF | Blueprint Medicines Corporation (US) | 2023-09-06 | — | — | EP | disclosed |
| WO-2022094354-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS, AND MEDICINAL APPLICATIONS THEREOF | LENGO THERAPEUTICS, INC. (US) | 2022-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240051945-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS, AND MEDICINAL APPLICATIONS THEREOF | TYMP, DPYD, TYMS | DDR2 3832/4885KDR 2159/4885AURKB 444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.